{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:21:56Z","timestamp":1792783316966,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011772","name":"Novartis Farmac\u00e9utica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3 Instituci\u00f3 dels Centres de Recerca de Catalunya","id":[{"id":"https:\/\/ror.org\/01bkbaq61","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR\u2009+\u2009\/HER2\u2009\u2212) breast cancer (BC) is the most frequently diagnosed subtype of BC, accounting for approximately 70% of cases. The introduction of cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6i) in combination with endocrine therapy (ET) has significantly improved clinical outcomes and transformed the therapeutic landscape of HR\u2009+\u2009\/HER2\u2009\u2212 in both the metastatic and early settings.<\/jats:p>\n                  <jats:p>Hepatotoxicity associated with CDK4\/6i is increasingly recognized as a clinically relevant adverse event. Most cases are asymptomatic, occur early during treatment, and resolve with dose modification or management according to the Summary of Product Characteristics (SmPC). However, variability in monitoring and management persists in clinical practice. Key issues, such as corticosteroid use, treatment continuation and reintroduction of the CDK4\/6i (either the same compound or another among the three globally approved agents) after liver toxicity recovery, remain insufficiently addressed by current evidence, despite the need for routine clinical decision-making.<\/jats:p>\n                  <jats:p>To address these gaps, a Spanish multidisciplinary panel of hepatologists and medical oncologists developed expert consensus recommendations on liver toxicity in patients with HR\u2009+\u2009\/HER2\u2009\u2212\u2009BC receiving CDK4\/6i. This consensus provides practical guidance on the classification, monitoring and management of liver-related adverse events during CDK4\/6i therapy and promotes proactive collaboration between oncology and hepatology teams to support treatment continuity and optimize patient outcomes.<\/jats:p>","DOI":"10.1007\/s12094-026-04369-7","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T12:48:11Z","timestamp":1778417291000},"page":"4546-4559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expert consensus on optimal management of liver-related adverse events during CDK4\/6 inhibitor therapy"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1485-5080","authenticated-orcid":false,"given":"Sonia","family":"Pernas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-1764","authenticated-orcid":false,"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-0236","authenticated-orcid":false,"given":"Olga","family":"Mart\u00ednez-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1565-0757","authenticated-orcid":false,"given":"Ra\u00fal","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4837-9051","authenticated-orcid":false,"given":"Alberto","family":"Amador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2253-739X","authenticated-orcid":false,"given":"Elena","family":"L\u00f3pez-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7773-5994","authenticated-orcid":false,"given":"Bego\u00f1a","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0326-4119","authenticated-orcid":false,"given":"Beatriz","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3894-0765","authenticated-orcid":false,"given":"Monica","family":"Cejuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2886-3794","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0410-079X","authenticated-orcid":false,"given":"Patricia Palacios","family":"Ozores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9309-2052","authenticated-orcid":false,"given":"Mar","family":"Riveiro-Barciela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8859-8307","authenticated-orcid":false,"given":"Meritxell","family":"Bellet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"4369_CR1","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. (2024).Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. Available from: https:\/\/gco.iarc.who.int\/today. Accessed: April 2026"},{"key":"4369_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016.","journal-title":"Ann Oncol"},{"key":"4369_CR3","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1607303.","journal-title":"N Engl J Med"},{"key":"4369_CR4","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","volume":"23","author":"MN Dickler","year":"2017","unstructured":"Dickler MN, Tolaney SM, Rugo HS, Cort\u00e9s J, Di\u00e9ras V, Patt D, et al. MONARCH 1: a phase II study of abemaciclib as a single agent in HR+\/HER2\u2212 metastatic breast cancer. Clin Cancer Res. 2017;23:5218\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0754.","journal-title":"Clin Cancer Res"},{"key":"4369_CR5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2114663.","journal-title":"N Engl J Med"},{"key":"4369_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/0284186X.2018.1532603","volume":"58","author":"TM B\u00f8ttcher","year":"2019","unstructured":"B\u00f8ttcher TM, Cold S, Jensen AB. Treatment of advanced HR+\/HER2\u2212 breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib. Acta Oncol. 2019;58:147\u201353. https:\/\/doi.org\/10.1080\/0284186X.2018.1532603.","journal-title":"Acta Oncol"},{"key":"4369_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0651-4","volume":"20","author":"CG Murphy","year":"2019","unstructured":"Murphy CG. The role of CDK4\/6 inhibitors in breast cancer. Curr Treat Options Oncol. 2019;20:52. https:\/\/doi.org\/10.1007\/s11864-019-0651-4.","journal-title":"Curr Treat Options Oncol"},{"key":"4369_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.21.02554","volume":"40","author":"M Gnant","year":"2021","unstructured":"Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, et al. Adjuvant palbociclib for early breast cancer: the PALLAS Trial results (ABCSG-42\/AFT-05\/BIG-14-03). J Clin Oncol. 2021;40:282\u201393. https:\/\/doi.org\/10.1200\/JCO.21.02554.","journal-title":"J Clin Oncol"},{"key":"4369_CR9","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1200\/JCO.20.03639","volume":"39","author":"S Loibl","year":"2021","unstructured":"Loibl S, Marm\u00e9 F, Martin M, Untch M, Bonnefoi H, Kim S-B, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer\u2014the Penelope-B trial. J Clin Oncol. 2021;39:1518\u201330. https:\/\/doi.org\/10.1200\/JCO.20.03639.","journal-title":"J Clin Oncol"},{"key":"4369_CR10","doi-asserted-by":"publisher","first-page":"e14591","DOI":"10.1200\/JCO.2019.37.15_suppl.e14591","volume":"37","author":"F Farooq","year":"2025","unstructured":"Farooq F, Cohen JA. Efficacy and toxicity of CDK 4\/6 inhibitors in breast cancer: systematic review and meta-analysis of the phase III clinical trials. J Clin Oncol. 2025;37:e14591\u2013e14591. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.e14591.","journal-title":"J Clin Oncol"},{"key":"4369_CR11","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.21037\/apm-21-1096","volume":"10","author":"L Yang","year":"2021","unstructured":"Yang L, Xue J, Yang Z, Wang M, Yang P, Dong Y, et al. Side effects of CDK4\/6 inhibitors in the treatment of HR+\/HER2\u2212 advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med. 2021;10:5590\u20139. https:\/\/doi.org\/10.21037\/apm-21-1096.","journal-title":"Ann Palliat Med"},{"key":"4369_CR12","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987\u201398. https:\/\/doi.org\/10.1200\/JCO.20.02514.","journal-title":"J Clin Oncol"},{"key":"4369_CR13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390:1080\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2305488.","journal-title":"N Engl J Med"},{"key":"4369_CR14","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for hr-positive, advanced breast cancer. N Engl J Med. 2016;375:1738\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1609709.","journal-title":"N Engl J Med"},{"key":"4369_CR15","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1200\/JCO.24.00144","volume":"42","author":"Y-S Lu","year":"2024","unstructured":"Lu Y-S, Mahidin EIBM, Azim H, Eralp Y, Yap YS, Im S-A, et al. Final results of RIGHT choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer. J Clin Oncol. 2024;42:2812\u201321. https:\/\/doi.org\/10.1200\/JCO.24.00144.","journal-title":"J Clin Oncol"},{"key":"4369_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1055\/s-0044-1791768","volume":"14","author":"PM Parikh","year":"2025","unstructured":"Parikh PM, Vora A, Yadav R, Kapoor A, Sahoo T, Rajappa S, et al. Consensus guidelines for the use of cyclin-dependent kinase (CDK) 4\/6 inhibitors in the management of hormone receptor positive (HR+ve), Her2\u2212ve early breast cancer (EBC). South Asian J Cancer. 2025;14:45\u201352. https:\/\/doi.org\/10.1055\/s-0044-1791768.","journal-title":"South Asian J Cancer"},{"key":"4369_CR17","unstructured":"Common terminology criteria for adverse events (CTCAE) v 5.0. 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.html"},{"key":"4369_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101098","volume":"6","author":"L Meunier","year":"2024","unstructured":"Meunier L, De Martin E, Delire B, Jacot W, Guiu S, Zahhaf A, et al. CDK4\/6 inhibitor-induced liver injury: clinical phenotypes and role of corticosteroid treatment. JHEP Rep. 2024;6:101098. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101098.","journal-title":"JHEP Rep"},{"key":"4369_CR19","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Aithal GP, Bj\u00f6rnsson ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, et al. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70:1222\u201361. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014.","journal-title":"J Hepatol"},{"key":"4369_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01235","author":"E Raschi","year":"2019","unstructured":"Raschi E, De Ponti F. Strategies for early prediction and timely recognition of drug-induced liver injury: the case of cyclin-dependent kinase 4\/6 inhibitors. Front Pharmacol. 2019. https:\/\/doi.org\/10.3389\/fphar.2019.01235.","journal-title":"Front Pharmacol"},{"key":"4369_CR21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806\u201315. https:\/\/doi.org\/10.1038\/clpt.2011.58.","journal-title":"Clin Pharmacol Ther"},{"key":"4369_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40264-018-0743-2","volume":"42","author":"M Real","year":"2019","unstructured":"Real M, Barnhill MS, Higley C, Rosenberg J, Lewis JH. Drug-induced liver injury: highlights of the recent literature. Drug Saf. 2019;42:365\u201387. https:\/\/doi.org\/10.1007\/s40264-018-0743-2.","journal-title":"Drug Saf"},{"key":"4369_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Chalasani N, Bj\u00f6rnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, et al. Drug-induced liver injury. Nat Rev Dis Primers. 2019;5:58. https:\/\/doi.org\/10.1038\/s41572-019-0105-0.","journal-title":"Nat Rev Dis Primers"},{"key":"4369_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1247270","author":"ME Cazzaniga","year":"2023","unstructured":"Cazzaniga ME, Ciaccio A, Danesi R, Duhoux FP, Girmenia C, Zaman K, et al. Late onset toxicities associated with the use of CDK 4\/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1247270.","journal-title":"Front Oncol"},{"key":"4369_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1378090","author":"Y She","year":"2024","unstructured":"She Y, Guo Z, Zhai Q, Liu J, Du Q, Zhang Z. CDK4\/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug\u2013gene interaction network. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/fphar.2024.1378090.","journal-title":"Front Pharmacol"},{"key":"4369_CR26","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/S0168-8278(25)00348-4","volume":"82","author":"M Riveiro-Barciela","year":"2025","unstructured":"Riveiro-Barciela M, Esteban P, Vega-Cano KS, Mu\u00f1oz BM, L\u00f3pez-Miranda E, Jara P, et al. OS-033 Liver injury induced by CDK4\/6 inhibitors for metastatic breast cancer: characterization and management. Data from a multicenter study. J Hepatol. 2025;82:S29-30. https:\/\/doi.org\/10.1016\/S0168-8278(25)00348-4.","journal-title":"J Hepatol"},{"key":"4369_CR27","unstructured":"European Commission. Ibrance: Summary of product characteristics [Internet]. Brussels: European Commission; 2016 [cited 2025 Apr 29]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20161109136168\/anx_136168_en.pdf"},{"key":"4369_CR28","unstructured":"European Medicines Agency. Kisqali: EPAR - Product information [Internet]. Amsterdam: EMA; 2024 [cited 2025 Apr 29]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kisqali-epar-product-information_en.pdf"},{"key":"4369_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918793326","author":"M Thill","year":"2018","unstructured":"Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol. 2018. https:\/\/doi.org\/10.1177\/1758835918793326.","journal-title":"Ther Adv Med Oncol"},{"key":"4369_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919833867","volume":"11","author":"M Bellet","year":"2019","unstructured":"Bellet M, Ahmad F, Villanueva R, Valdivia C, Palomino-Doza J, Ruiz A, et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol. 2019;11:1758835919833867. https:\/\/doi.org\/10.1177\/1758835919833867.","journal-title":"Ther Adv Med Oncol"},{"key":"4369_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103335","author":"N Harbeck","year":"2024","unstructured":"Harbeck N, Jacot W, Ezquerra MB, Tolaney SM, Rugo HS, Cardoso F, et al. 277P Descriptive analysis of hepatic safety for patients (pts) with HR+\/HER2\u2212; breast cancer (BC) treated with ribociclib (RIB) + endocrine therapy (ET). ESMO Open. 2024. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103335.","journal-title":"ESMO Open"},{"key":"4369_CR32","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.21873\/anticanres.16114","volume":"42","author":"A Taniguchi","year":"2022","unstructured":"Taniguchi A, Kittaka N, Kanaoka H, Nakajima S, Oyama Y, Seto Y, et al. Risk of abemaciclib-induced liver injury in hormone receptor-positive, HER2-negative metastatic breast cancer: a retrospective analysis. Anticancer Res. 2022;42:6027\u201335. https:\/\/doi.org\/10.21873\/anticanres.16114.","journal-title":"Anticancer Res"},{"key":"4369_CR33","doi-asserted-by":"publisher","first-page":"ix13","DOI":"10.1093\/annonc\/mdz418","volume":"30","author":"S-A Im","year":"2019","unstructured":"Im S-A. Pooled analysis of efficacy and safety in Asian patients (pts) in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials of ribociclib (RIB) plus endocrine therapy (ET). Ann Oncol. 2019;30:ix13\u20134. https:\/\/doi.org\/10.1093\/annonc\/mdz418.","journal-title":"Ann Oncol"},{"issue":"4","key":"4369_CR34","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3305\/nh.2012.27.4.5890","volume":"27","author":"M Alves de Carvalho","year":"2012","unstructured":"Alves de Carvalho M, Coelho Cabral P, de Kruze Grande Arruda I, de Goretti Pessoa Ara\u00fajo Burgos MA, Silva Diniz AD, Barros Pernambuco JR, et al. Factores asociados a la esteatosis hep\u00e1tica un estudio en pacientes del nordeste brasile\u00f1o. Nutr Hosp. 2012;27(4):1344\u201350. https:\/\/doi.org\/10.3305\/nh.2012.27.4.5890.","journal-title":"Nutr Hosp"},{"key":"4369_CR35","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1590\/S1516-31802010000600006","volume":"128","author":"JL Narciso-Schiavon","year":"2010","unstructured":"Narciso-Schiavon JL, Schiavon LDL, De Carvalho-Filho RJ, Hayashida DY, Wang JHJ, Souza TS, et al. Clinical characteristics associated with hepatic steatosis on ultrasonography in patients with elevated alanine aminotransferase. Sao Paulo Med J. 2010;128:342\u20137. https:\/\/doi.org\/10.1590\/S1516-31802010000600006.","journal-title":"Sao Paulo Med J"},{"key":"4369_CR36","doi-asserted-by":"publisher","first-page":"S404","DOI":"10.1016\/S0168-8278(22)01153-9","volume":"77","author":"M Scaravaglio","year":"2022","unstructured":"Scaravaglio M, Ciaccio A, Laffusa A, Luc\u00e1 M, Longo S, Manna M, et al. Liver toxicity associated to novel cyclin-dependent kinase inhibitor ribociclib in a cohort of advanced breast cancer patients. J Hepatol. 2022;77:S404\u20135. https:\/\/doi.org\/10.1016\/S0168-8278(22)01153-9.","journal-title":"J Hepatol"},{"key":"4369_CR37","unstructured":"Mascar\u00f3-Baselga P, Sharela-Vega-Cano K, Yaringa\u00f1o J, Mirallas O, Filippi-Arriaga F, Zamora E, et al. Hepatotoxicidad asociada a inhibidores de quinasas dependientes de ciclinas 4\/6 (iCDK) en tratamiento de 1L de c\u00e1ncer mama metast\u00e1sico (CMM) RH+\/HER2\u2212. Presented at: SEOM Congress; 2023; 19\u201322; Barcelona, Spain"},{"key":"4369_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101438","author":"KS Vega-Cano","year":"2023","unstructured":"Vega-Cano KS, Mascaro P, Mirallas O, Filippi-Arriaga F, Joval L, Zamora E, et al. 250P Liver toxicity (LT) in patients (pts) with ER-positive HER2-negative metastatic breast cancer (MBC) treated with first-line Cyclin-Dependent Kinase 4\/6 inhibitors (CDKi). ESMO Open. 2023. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101438.","journal-title":"ESMO Open"},{"key":"4369_CR39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"J-H Lee","year":"2010","unstructured":"Lee J-H, Kim D, Kim HJ, Lee C-H, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42:503\u20138. https:\/\/doi.org\/10.1016\/j.dld.2009.08.002.","journal-title":"Dig Liver Dis"},{"key":"4369_CR40","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.1016\/S1590-8658(22)00444-3","volume":"54","author":"A Ciaccio","year":"2022","unstructured":"Ciaccio A, Scaravaglio M, Laffusa A, Luc\u00e1 M, Longo S, Manna M, et al. T.08.1 Characteristics and predictors of liver toxicity in advanced breast cancer patients treated with cyclin dependent kinase inhibitors: an observational study. Dig Liver Dis. 2022;54:S146\u20137. https:\/\/doi.org\/10.1016\/S1590-8658(22)00444-3.","journal-title":"Dig Liver Dis"},{"key":"4369_CR41","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(18)30292-4.","journal-title":"Lancet Oncol"},{"key":"4369_CR42","doi-asserted-by":"publisher","first-page":"PD17-12","DOI":"10.1158\/1538-7445.SABCS22-PD17-12","volume":"83","author":"F Cardoso","year":"2023","unstructured":"Cardoso F, Jacot W, K\u00fcemmel S, Gupta S, Balaraman R, Lebedeva L, et al. Abstract PD17-12: primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+\/HER2\u2212 advanced breast cancer. Cancer Res. 2023;83:PD17-12-PD17-12. https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-PD17-12.","journal-title":"Cancer Res"},{"key":"4369_CR43","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/10781552211027931","volume":"28","author":"A Topcu","year":"2022","unstructured":"Topcu A, Yasin AI, Shbair AT, Besiroglu M, Simsek M, Sucuoglu Z, et al. A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer. J Oncol Pharm Pract. 2022;28:242\u20136. https:\/\/doi.org\/10.1177\/10781552211027931.","journal-title":"J Oncol Pharm Pract"},{"key":"4369_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/0284186X.2020.1853228","volume":"60","author":"S Finnsdottir","year":"2021","unstructured":"Finnsdottir S, Sverrisdottir A, Bj\u00f6rnsson ES. Hepatotoxicity associated with ribociclib among breast cancer patients. Acta Oncol. 2021;60:195\u20138. https:\/\/doi.org\/10.1080\/0284186X.2020.1853228.","journal-title":"Acta Oncol"},{"key":"4369_CR45","unstructured":"FDA Guidance for industry: drug-induced liver injury: premarketing clinical evaluation. Available at: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htmorTel:800-835-4709or301-827-1800http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.html (2009). Last access: May 2025"},{"key":"4369_CR46","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.09.011","author":"N Chalasani","year":"2008","unstructured":"Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008. https:\/\/doi.org\/10.1053\/j.gastro.2008.09.011.","journal-title":"Gastroenterology"},{"key":"4369_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1256783","author":"S Schaeffer","year":"2023","unstructured":"Schaeffer S, Lutz C, Dobbie M, Terracciano LM, Matter M, Vosbeck J, et al. Ribociclib-induced liver injury: a case report. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1256783.","journal-title":"Front Oncol"},{"key":"4369_CR48","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638\u201346. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155.","journal-title":"J Clin Oncol"},{"key":"4369_CR49","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge","year":"2017","unstructured":"Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875\u201384. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585.","journal-title":"J Clin Oncol"},{"key":"4369_CR50","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im S-A, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1810527.","journal-title":"N Engl J Med"},{"key":"4369_CR51","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im S-A, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465\u201372. https:\/\/doi.org\/10.1200\/JCO.2018.78.9909.","journal-title":"J Clin Oncol"},{"key":"4369_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103101","author":"CH Barrios","year":"2024","unstructured":"Barrios CH, Harbeck N, Hortobagyi GN, O\u2019Shaughnessy J, Huang C-S, Jimenez MM, et al. 113MO NATALEE update: safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+\/HER2\u2212 early breast cancer (EBC). ESMO Open. 2024. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103101.","journal-title":"ESMO Open"},{"key":"4369_CR53","doi-asserted-by":"publisher","first-page":"S306","DOI":"10.1016\/j.annonc.2025.08.725","volume":"36","author":"PH Cottu","year":"2025","unstructured":"Cottu PH, Prat A, Pascual T, Hu H, Roux E, Salvador Bofill FJ, et al. 296O risk of recurrence (ROR) after neoadjuvant ribociclib plus ET in clinically high-risk ER+\/HER2\u2212 BC: preliminary analysis of the SOLTI-RIBOLARIS trial. Ann Oncol. 2025;36:S306\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.725.","journal-title":"Ann Oncol"},{"key":"4369_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104926","volume":"10","author":"W Jacot","year":"2025","unstructured":"Jacot W, Lu Y-S, Tolaney SM, Rugo HS, Ezquerra MB, Cardoso F, et al. 355P dynamic analysis of liver enzyme elevation in patients (pts) with HR+\/HER2\u2212 advanced breast cancer (ABC) treated with first-line (1L) ribociclib (RIB). ESMO Open. 2025;10:104926. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104926.","journal-title":"ESMO Open"},{"key":"4369_CR55","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425\u201339. https:\/\/doi.org\/10.1016\/S1470-2045(15)00613-0.","journal-title":"Lancet Oncol"},{"key":"4369_CR56","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29:1541\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdy155.","journal-title":"Ann Oncol"},{"key":"4369_CR57","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor\u2013positive advanced breast cancer. N Engl J Med. 2015;373:209\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1505270.","journal-title":"N Engl J Med"},{"key":"4369_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104922","volume":"10","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Lu Y-S, Tarantino P, Brezden-Masley C, Mouabbi JA, Gombos A, et al. 351P real-world (RW) analysis of alanine aminotransferase (ALT)\/aspartate aminotransferase (AST) elevation in patients (pts) with metastatic breast cancer (MBC) treated with ribociclib (RIB). ESMO Open. 2025;10:104922. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104922.","journal-title":"ESMO Open"},{"key":"4369_CR59","doi-asserted-by":"publisher","first-page":"S1099","DOI":"10.1016\/j.annonc.2024.08.1969","volume":"35","author":"O Bas","year":"2024","unstructured":"Bas O, Inci BK, Eroglu I, Efil SC, Kaya S, Kubilay Tolunay P, et al. 1875P real-world evidence of ribociclib induced liver toxicity in patients with breast cancer: a multi-center experience. Ann Oncol. 2024;35:S1099\u2013S1099. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1969.","journal-title":"Ann Oncol"},{"key":"4369_CR60","unstructured":"European Medicines Agency. Verzenios: EPAR \u2013 Product information [Internet]. Amsterdam: EMA; 2024 [cited 2025 Apr 29]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/verzenios-epar-product-information_en.pdf"},{"key":"4369_CR61","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3892\/ol.2024.14278","volume":"27","author":"M Teomete","year":"2024","unstructured":"Teomete M, Cabuk D, Korkmaz T, Seber S, Ozturk O, Aver B, et al. Recommendations for cyclin dependent kinase 4\/6 inhibitor treatments in the context of co morbidity and drug interactions (Review). Oncol Lett. 2024;27:145. https:\/\/doi.org\/10.3892\/ol.2024.14278.","journal-title":"Oncol Lett"},{"key":"4369_CR62","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1093\/annonc\/mdr486","volume":"23","author":"MD Danese","year":"2012","unstructured":"Danese MD, O\u2019Malley C, Lindquist K, Gleeson M, Griffiths RI. An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer. Ann Oncol. 2012;23:1756\u201365. https:\/\/doi.org\/10.1093\/annonc\/mdr486.","journal-title":"Ann Oncol"},{"key":"4369_CR63","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cncr.28509","volume":"120","author":"BK Edwards","year":"2014","unstructured":"Edwards BK, Noone A-M, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290\u2013314. https:\/\/doi.org\/10.1002\/cncr.28509.","journal-title":"Cancer"},{"key":"4369_CR64","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000499534","volume":"14","author":"J Ettl","year":"2019","unstructured":"Ettl J. Management of adverse events due to cyclin-dependent kinase 4\/6 inhibitors. Breast Care Basel. 2019;14:86\u201392. https:\/\/doi.org\/10.1159\/000499534.","journal-title":"Breast Care Basel"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04369-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04369-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04369-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:41:46Z","timestamp":1790160106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04369-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":64,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4369"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04369-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sonia Pernas: consulting or advisory role\u2014Eli Lilly; Novartis; Pfizer, Daiichi Sankyo\/AstraZeneca; Reveal, MSD\/Merck, Gebro Pharma, and Jiangsu Hengrui; speakers\u2019 bureau\u2014Novartis, Lilly, Roche, Gilead Sciences, Pfizer, Daiichi Sankyo\/AstraZeneca; research funding: Roche (Inst); travel, accommodations\u00a0for medical congresses\u2014Menarini, Gilead Sciences, Novartis; AstraZeneca, Roche, Pfizer; uncompensated relationships: SOLTI (board of directors). Xavier Forns: received consulting fees from Novartis.Olga Mart\u00ednez: O.M.S reports advisory\/consulting fees from Reveal Genomics, Roche and AstraZeneca, lecture fees from Daiichi Sankyo, Novartis, Pfizer and Eisai and travel expenses from Gilead and Novartis. Ra\u00fal Andrade: Consultant\/Advisor: Abbott, Bayer, BMS, Boehringer Ingelheim, ENYO, GSK, iQure, Inventiva, Johnson & Johnson, Kainos Medicine, Roche, Ryvu Therapeutics, Sanofi. Elena L\u00f3pez-Miranda: Honoraria and advisor collaboration\u2014AstraZeneca and Daiichi Sankyo. Support for attending meetings and\/or travel: Gilead, Daiichi Sankyo, Novartis and Roche. Bego\u00f1a Bermejo: receiving fees for medical education as consulting or advisory role with Lilly, Pfizer, Menarini, Astra Zeneca, GILEAD, Novartis, Roche. Participating in a speakers\u2019 bureau with Roche, MSD, Daiichi, Sankyo Astra Zeneca, Novartis, Lilly, Gilead. Travel, accommodation\u00a0by Pfizer, Roche and Daiichi Sankyo. Beatriz Mateos: Gilead:\u00a0payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events; ABBVIE: Support for attending meetings and\/or travel. M\u00f3nica Cejuela Sol\u00eds: declares financial relationships with Novartis, Pfizer, and Lilly, including grants for patient care improvement programs, participation in advisory boards, speaker honoraria and company-sponsored travel and accommodation. Patricia Palacios: Presentations, conference attendance, and travel expenses: AstraZeneca, Daiichi Sankyo, GSK, Lilly, Pfizer, MSD. Advisory Boards: GSK, Novartis, Clovis. Meritxell Bellet: Advisory Board: Pfizer, Novartis, Lilly, Stemline Menarini, Daiichi Sankyo. Speakers Bureau. Pfizer, Novartis, Lilly, Stemline Menarini, Daiichi Sankyo. Travel expenses: Pfizer, Novartis, Stemline Menarini, Roche. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript reports an expert consensus based on a structured review of previously published studies.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No primary research involving human participants or animals was conducted by the authors.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}